WebMay 23, 2024 · By William White, InvestorPlace Writer May 23, 2024, 10:36 am EDT. Catalyst Biosciences (NASDAQ: CBIO) stock is jumping on the sale of its protease medicines portfolio. Vertex Pharmaceuticals ... WebFeb 28, 2024. Catalyst Biosciences Provides Corporate Update. Read more. Dec 27, 2024. Catalyst Biosciences Completes First Steps in Reverse Merger Plan. Read more. Sep 01, 2024. Catalyst Biosciences, Inc. Announces September 21, 2024 as the Ex-Dividend Date … March 30, 2024: 10-K: Annual report which provides a comprehensive overview of … Catalyst Biosciences 611 Gateway Blvd., Suite 120, South San Francisco, CA 94080 Catalyst is a biopharmaceutical company focused on protease therapeutics to … DalcA is a next-generation SQ Factor IX product candidate for the prophylactic … Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX … Contact Catalyst Biosciences. Catalyst Biosciences 611 Gateway Blvd., Suite … Catalyst Biosciences 611 Gateway Blvd., Suite 120, South San Francisco, CA 94080 The Investor Relations website contains information about Catalyst Biosciences's … The Board of Directors of Catalyst Biosciences, Inc. (the "Company") sets …
Catalyst Biosciences – The protease medicines company
WebWe would like to show you a description here but the site won’t allow us. WebApr 6, 2024 · 03/30. Catalyst Biosciences, Inc. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) AQ. 03/30. CATALYST BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) AQ. Summary. Quotes. the horror sound
CBIO - Catalyst Biosciences, Inc. Stock Price and Quote
WebAug 25, 2024 · About Catalyst Biosciences Catalyst is a biopharmaceutical company focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems. After the ... WebContact Email [email protected]. Phone Number +1 650 871 0761. Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. It is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and … WebSep 1, 2024 · Catalyst Biosciences, Inc. Announces September 21, 2024 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share the horror star 1983